Clinical Trials Logo

Bloodloss clinical trials

View clinical trials related to Bloodloss.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00888940 Completed - Clinical trials for Surgical Procedures, Operative

Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery

CONSERV-2
Start date: June 2009
Phase: Phase 2
Study type: Interventional

A Phase 2 Randomized Double-Blind Active-Controlled Study in Subjects Exposed to Cardio-pulmonary Bypass During Cardiac Surgery at High Risk of Bleeding

NCT ID: NCT00816023 Completed - Clinical trials for Surgical Procedures, Operative

A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume

CONSERV-1
Start date: March 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and identify the optimal dose(s) of ecallantide in reducing blood loss in subjects undergoing coronary artery bypass surgery including the use of cardio pulmonary bypass.

NCT ID: NCT00777166 Completed - Myocardial Ischemia Clinical Trials

Cardiac Effects of Oxytocin Administrated During Cesarean Section, Signs of Myocardial Ischemia

Start date: December 2005
Phase: Phase 4
Study type: Interventional

Oxytocin has cardio vascular effects as hypotension, tachycardia and possibly coronary spasm. The uterotonic effect of the drug is used during cesarean section, to minimize blood loss.ECG changes suggestive of cardiac ischemia (ST depression) has been showed in previous studies of patients undergoing cesarean section i regional anaesthesia. The effect of oxytocin on this outcome has not been investigated to any extent. In the current study, we tested the hypothesis that there was no difference in occurrence of ECG changes (ST segment depression) between two doses of oxytocin. Participants were randomized to receive either 5 or 10 units of oxytocin in a double blinded fashion. Main outcome measure is occurrence of significant ST depression on ECG. Secondary outcome measures are mean arterial pressure, heart rate, blood loss, symptoms as chest pain, shortness of breath and feeling of heaviness on the chest.